Helixconstraints and amino acid substitution in GLP-1 increase cAMP and insulin secretion but not beta-arrestin 2 signaling-Reference-Cited by-同舟云学术

Helixconstraints and amino acid substitution in GLP-1 increase cAMP and insulin secretion but not beta-arrestin 2 signaling

Published:2017-02 Issue: Volume:127 Page:703-714
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Plisson Fabien,Hill Timothy A.,Mitchell Justin M.,Hoang Huy N.,de Araujo Aline D.,Xu Weijun,Cotterell Adam,Edmonds David J.,Stanton Robert V.,Derksen David R.,Loria Paula M.,Griffith David A.,Price David A.,Liras Spiros,Fairlie David P.

Funder

Australian National Health and Medical Research Council

Australian Research Council

Centre of Excellence in Advanced Molecular Imaging

Pfizer Emerging Science fund

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference60 articles.

1. Insights into the structure of class B GPCRs;Hollenstein;Trends Pharmacol. Sci.,2014

2. Targeting the glucagon receptor family for diabetes and obesity therapy;Cho;Pharmacol. Ther.,2012

3. Link between obesity and type 2 diabetes;Golay;B. Prac. Res. Clin. Endo. Metab.,2005

4. Design and synthesis of conformationally constrained glucagon-like Peptide-1 derivatives with increased plasma stability and prolonged in vivo activity;Miranda;J. Med. Chem.,2008

5. Biology of incretins: GLP-1 and GIP;Baggio;Gastroenterology,2007

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glucagon-like peptide-1 analogs: Miracle drugs are blooming?;European Journal of Medicinal Chemistry;2024-04

2. Recent Advances of Cell-Penetrating Peptides and Their Application as Vectors for Delivery of Peptide and Protein-Based Cargo Molecules;Pharmaceutics;2023-08-07

3. Modifying a Hydroxyl Patch in Glucagon-like Peptide 1 Produces Biased Agonists with Unique Signaling Profiles;Journal of Medicinal Chemistry;2022-08-19

4. Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP;Drug Design, Development and Therapy;2022-05

5. The therapeutic potential of GLP‐1 receptor biased agonism;British Journal of Pharmacology;2021-05-20